Ozempic’s hidden pregnancy risk few women know about

A new study, published in the Medical Journal of Australia, has cast a critical spotlight on the widespread use of GLP-1 receptor agonists among Australian women of childbearing age, revealing a significant gap in contraceptive use and raising alarms about potential risks during pregnancy. The groundbreaking research, spearheaded by Flinders University, underscores a concerning disconnect between the surging popularity of these medications, increasingly prescribed for weight loss, and the consistent application of essential reproductive health considerations in clinical practice. The findings suggest that while these drugs offer substantial benefits, their use among a demographic with high fertility potential necessitates urgent revisions to prescribing protocols and patient counseling.

The Rise of GLP-1 Receptor Agonists: A Paradigm Shift in Treatment

GLP-1 receptor agonists, a class of medications including well-known names like Ozempic (semaglutide), Wegovy (semaglutide), and Mounjaro (tirzepatide), were originally developed and approved for the management of type 2 diabetes. Their mechanism of action involves mimicking the incretin hormone glucagon-like peptide-1 (GLP-1), which helps regulate blood sugar by stimulating insulin release, suppressing glucagon secretion, and slowing gastric emptying. Beyond their glycemic control benefits, an observed side effect of these medications was significant weight loss, attributed to their ability to induce satiety and reduce appetite.

This potent weight-loss effect rapidly propelled GLP-1 receptor agonists into the mainstream as a highly sought-after treatment for obesity and overweight conditions. The demand has surged globally, leading to supply shortages in many regions, including Australia. Initially, the off-label use for weight loss was observed, but with subsequent approvals for obesity treatment, their prescription for non-diabetic weight management has become increasingly common. This transition marks a significant paradigm shift, extending their reach far beyond their original indication and into a broader patient demographic, including many women in their reproductive years.

Flinders University Study: Unveiling Critical Gaps

The Flinders University study delved into an extensive dataset, analyzing records from over 1.6 million Australian women aged 18 to 49 who attended general practices between 2011 and 2022. This comprehensive review provided a robust foundation for understanding prescribing patterns and associated patient behaviors. Out of this vast cohort, 18,010 women initiated treatment with GLP-1 receptor agonists during the study period. The findings were stark: a mere 21% of these women had reported using effective contraception at the time of their prescription.

Associate Professor Luke Grzeskowiak, a pharmacist and lead author from the College of Medicine and Public Health at Flinders University, highlighted the dramatic shift in prescription patterns. "We’re seeing widespread use of these medications among women of childbearing age, but very little evidence that contraception is being considered as part of routine care," he stated. His analysis revealed that in 2022 alone, more than 6,000 women began treatment with GLP-1s, and strikingly, over 90% of them did not have a diabetes diagnosis. This data unequivocally demonstrates that the primary driver for GLP-1 prescriptions in this demographic has shifted from diabetes management to weight loss, intensifying the need for careful consideration of reproductive health.

The study further identified concerning pregnancy rates within this cohort. Approximately 2.2% of women became pregnant within six months of commencing GLP-1 treatment. The risk of unintended pregnancy was found to be highest among younger women already diagnosed with diabetes, and, perhaps counter-intuitively, also among non-diabetic women in their early thirties. A particularly salient finding was the increased likelihood of conception among women with polycystic ovary syndrome (PCOS), who were twice as likely to conceive. This suggests that the weight loss induced by GLP-1s may inadvertently improve fertility in women struggling with conditions like PCOS, leading to unintended pregnancies where contraception is not in use. Crucially, the research confirmed that women who were using contraception at the time of prescribing had a significantly lower risk of pregnancy, underscoring the effectiveness of preventive measures when properly implemented.

The Unseen Risks: Potential Fetal Development Concerns

While the benefits of GLP-1 receptor agonists for weight management are increasingly recognized, the potential risks during pregnancy remain a significant concern, largely due to limited human data. Current knowledge primarily relies on animal studies and the pharmacological understanding of these drugs. A previous review of animal studies conducted by the University of Amsterdam linked GLP-1 exposure during pregnancy to reduced fetal growth and skeletal abnormalities. These findings, though not directly translatable to humans, serve as a critical warning sign. Animal models often provide the first indications of potential teratogenic effects, prompting caution in human use. The rapid developmental stages of a fetus make it particularly vulnerable to pharmacological interventions, and substances that cross the placental barrier could interfere with crucial growth processes.

Regulatory bodies and pharmaceutical manufacturers universally advise against the use of GLP-1 receptor agonists during pregnancy and recommend discontinuation several weeks to months before conception. For instance, product information for many GLP-1s explicitly states that these medications should not be used in pregnant women due to potential risks to the fetus and that women of childbearing potential should use effective contraception during treatment and for a specified period after discontinuation. The UK, for example, explicitly advises that women using GLP-1 receptor agonists should avoid pregnancy and use effective contraception. Associate Professor Grzeskowiak notes, however, that "this advice is not being followed consistently in Australian clinical practice," creating a dangerous gap between recommended guidelines and real-world application. The lack of robust human clinical trial data on pregnancy outcomes is largely due to ethical constraints, making it challenging to conduct randomized controlled trials in pregnant populations. Therefore, observational studies and pharmacovigilance become even more critical to gather real-world evidence on fetal safety.

A Call for Enhanced Clinical Practice and Patient Education

The findings from Flinders University highlight an urgent need for a more integrated approach to reproductive health counseling when prescribing GLP-1 receptor agonists to women of childbearing age. Associate Professor Grzeskowiak emphasized, "We need to ensure that reproductive health is part of every conversation when these drugs are prescribed to any women of childbearing age." This extends beyond merely mentioning the risks; it necessitates a comprehensive discussion about effective contraceptive options, the importance of consistent use, and the timeline for safely discontinuing the medication prior to attempting conception.

The current situation suggests a systemic failing in incorporating these crucial discussions into routine general practice. This could stem from various factors, including time pressures during consultations, a lack of standardized protocols, or an underestimation of the fertility impact of weight loss itself. The study’s authors stress the importance of clearer practice recommendations and guidelines for prescribers. Such guidelines would provide a structured framework for healthcare professionals, ensuring that critical reproductive health information is consistently communicated and documented. These recommendations could include mandatory discussions about contraception, referral to family planning services, and clear advice on how long women should wait after stopping the medication before trying to conceive.

Leading medical organizations, such as the Royal Australian College of General Practitioners (RACGP) and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), are expected to review these findings and potentially update their guidelines to reflect the growing evidence and concerns. Pharmaceutical companies, while providing warnings in their product information, may also need to support educational initiatives for healthcare providers to ensure their warnings are translated into practical clinical advice.

Broader Implications and Future Directions

The implications of this study extend beyond individual patient safety, touching upon public health, healthcare economics, and ethical considerations. Unintended pregnancies, especially those potentially complicated by medication exposure, can lead to increased healthcare costs, emotional distress for families, and a higher burden on maternal and child health services. The ethical dilemma lies in balancing the significant health benefits of GLP-1s for weight management with the imperative to protect vulnerable populations, such as unborn babies, from potential harm. Patient autonomy is paramount, but it must be informed by complete and accurate risk information.

The study’s authors unequivocally state that further studies evaluating the impact of these medications on pregnancy and unborn babies are warranted. This includes establishing pregnancy registries to systematically collect data on outcomes in women exposed to GLP-1s, conducting observational cohort studies, and exploring the pharmacokinetics of these drugs during pregnancy. Such research would provide much-needed human data to either confirm or refute the concerns raised by animal studies, leading to more definitive clinical advice.

In the interim, the immediate advice to women considering or currently taking GLP-1 receptor agonists is clear and consistent: "Speak to your GP about the risks and benefits of GLP-1 medicines before taking them, and only take those prescribed by a healthcare professional." This emphasizes the importance of a personalized approach to care, where individual health profiles, reproductive plans, and potential risks are thoroughly discussed with a qualified medical practitioner. Ensuring safe and effective use of these powerful medications requires a concerted effort from prescribers, patients, regulatory bodies, and researchers to bridge the existing knowledge and practice gaps.

Acknowledgements: Luke Grzeskowiak receives salary support from a Channel 7 Children’s Research Foundation Fellowship (CRF-210323). We also acknowledge the contributions of members of the SPHERE Centre of Research Excellence in Women’s Sexual and Reproductive Health in Primary Care (SPHERE 2.0 CRE), which is funded by the National Health and Medical Research Council (APP2024717).